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Introduction
ECM mineralization in bones and teeth is a genetically regu-
lated process. In humans, genetic mutations may lead to a vari-
ety of diseases affecting ECM mineralization in skeletal and 
dental tissues, which include X-linked hypophosphatemia, hypo-
phosphatasia, rickets, and some forms of osteogenesis/dentino-
genesis imperfecta (Tanaka and Deluca, 1974; Whyte, 1994; 
Nesbitt et al., 1999; Glorieux et al., 2002; Goldberg et al., 2008). 
Although considered as a critical physiological process, the mo-
lecular  mechanism  of  ECM  mineralization  is  still  not  fully   
understood. Identification of novel genetic regulators of this 
process and elucidation of their modes of action may lead to   
effective interventions for genetic diseases associated with abnor-
mal skeletal mineralization.
Our  current  understanding  suggests  that  skeletal  and   
dental ECM mineralization can be attributed to a large extent to 
the unique promineralization environment of these hard tissues. 
Two mineral ions, Pi and calcium, when present at physiological 
concentrations,  will  promote  apatitic  mineral  crystal  growth 
within and between newly synthesized collagen fibrils in the 
skeletal ECM (Murshed et al., 2005). Apart from the mineral 
ions themselves, extracellular levels of mineralization inhibi-
tors can also affect ECM mineralization (Luo et al., 1997; 
Okawa et al., 1998; Ho et al., 2000; Murshed et al., 2004). For 
example, >40 yr ago, it was shown that PPi, a chemical deriva-
tive of Pi, can potently inhibit the mineralization process (Fleisch 
and Bisaz, 1962; Terkeltaub, 2001). More recently, it has been 
shown that matrix gla protein (MGP), a small extracellular pro-
tein, prevents ECM mineralization in the cartilage and vascular 
tissues (Luo et al., 1997; Murshed et al., 2004).
Type 1 collagen, a scaffolding ECM protein, and tissue-
nonspecific alkaline phosphatase (ALPL [alkaline phosphatase, 
liver/bone/kidney]), an enzyme required for the cleavage of PPi 
in the bone matrix, are both necessary for normal bone mineral-
ization (Waymire et al., 1995; Hessle et al., 2002; Murshed   
et al., 2005). We recently demonstrated the importance of these 
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that nSMase2 activity in the brain regulates skeletal devel­
opment through endocrine factors. However, we detected 
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than the control osteoblast cultures. We next generated   
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nSMase2 in skeletal tissues.
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embryos and adult mice using skeletal preparations, micro-
computed  tomography  (micro-CT),  and  histology/histomorpho-
metric  analysis.  We  demonstrate  here  that  the  fro  mutation 
affects bone ECM mineralization in both embryos and in adult 
mice and that there is a delay of apoptosis in the hypertrophic 
chondrocytes in the developing fro/fro skeleton. We also show 
that osteoblast-specific expression of the Smpd3 transgene in 
fro/fro;Col1a1-Smpd3 mice completely rescues the bone mineral-
ization defects, whereas the cartilage phenotype that appears 
during early skeletal development remains unaffected. Our 
work establishes the fro mutation as the sole cause of skeletal 
abnormalities in the fro/fro mice and suggests a cell-autonomous, 
tissue-specific role for nSMase2 in the developing skeleton.
Results
Impaired bone mineralization in fro/fro mice
fro/fro neonates are characterized by a shortened body stature 
with skeletal abnormalities (Aubin et al., 2005). As shown by 
the skeletal preparations of the newborn mice, both flat (intra-
membranous) and long (endochondral) bones are affected—the 
parietal suture was poorly mineralized, whereas both fore- and 
hind limbs were severely bent in the fro/fro mutants (Fig. 1,   
A and B). Further analysis by micro-CT revealed a reduction of 
mineralized tissue in the flat bones of the skull and alveolar 
bones in the jaw (Fig. 1 C).
To further confirm that the observed decrease in mineral-
ized tissue was attributable purely to a mineralization defect, we 
examined wild-type (WT) and mutant mice for the presence of 
excess  osteoid,  the  proteinaceous  matrix  secreted  by  osteo-
blasts, which subsequently becomes mineralized. Histological 
analysis of the parietal bones in the skullcap of 2-d-old fro/fro 
mice revealed a severely hypomineralized matrix at the suture 
(Fig. 1 D, top). Also, there was a marked reduction of mineral-
ization in the alveolar bones from these mice (Fig. 1 D, bottom). 
By 1 mo of age, the trabecular bones of fro/fro mice showed an 
increase of 5% in osteoid volume over total bone volume as 
measured by histomorphometry (Fig. 1, E and F). Similarly, 
there was a significant increase in the osteoid surface in the   
fro/fro bones (Fig. 1 G). These results indicate that osteoid ECM 
is indeed deposited but is not efficiently mineralized. None of these 
skeletal abnormalities were seen in +/fro mice; therefore, we 
used these mice as controls for our subsequent in vivo analyses.
The fro mutation abolishes nSMase2 
activity but does not affect its  
membrane localization
The fro mutation causes a deletion in Smpd3, resulting in a re-
placement of the last 33 amino acids of nSMase2. In a previous 
study, reduced nSMase activity was reported in skin samples 
collected from fro/fro mice (Aubin et al., 2005). This reduced 
enzymatic activity can be caused by a loss of the catalytic site 
and/or by impaired membrane targeting of the enzyme. To in-
vestigate this, we generated two FLAG-tagged expression con-
structs CMV-Smpd3 and CMV-mSmpd3 encoding the WT and a 
mutated  nSMase2  that  carries  the  fro  mutation,  respectively 
(Fig. 2, A and B). The constructs were used to transfect MCF-7 
key determinants of ECM mineralization in an in vivo mouse 
model, in which Alpl forced expression in the dermis, a fibrillar, 
collagen-rich soft connective tissue, resulted in ectopic min-
eralization of the skin (Murshed et al., 2005). Although these   
findings established the concurrent requirements of a mineral-
scaffolding protein matrix and phosphatase activities in skeletal 
ECM mineralization, they did not rule out the existence of other 
mechanisms working in concert to regulate this process. A re-
cently identified mutation in a mouse model, which displays al-
tered sphingolipid metabolism and poorly mineralized skeletal 
tissues, further enforces the likelihood that multiple mecha-
nisms are involved in skeletal mineralization (Guenet et al., 
1981; Aubin et al., 2005).
Although initially considered as inert structural molecules, 
sphingolipids are now recognized as important mediators for 
signal transduction pathways affecting various cell functions 
(Merrill et al., 1997; Milhas et al., 2010; Wu et al., 2010). Bone 
deformities  in  mouse  models  lacking  a  functional  Smpd3  
(sphingomyelin phosphodiesterase 3) gene underscore the im-
portance of sphingolipid metabolism in skeletal tissues (Aubin 
et al., 2005; Stoffel et al., 2005). Smpd3 encodes neutral sphingo-
myelinase 2 (nSMase2), a membrane-bound enzyme, which 
cleaves sphingomyelin to generate the lipid second messen-
ger ceramide. Ceramide generated by sphingomyelinases or by 
a de novo pathway affects a wide range of cellular processes, 
including cell death, proliferation, and differentiation (Obeid   
et al., 1993; Bose et al., 1995; Richard et al., 1996; Sanchez-
Alavez et al., 2006).
In recent years, studies have provided useful perspectives 
on novel physiological roles for nSMase2 (Kolak et al., 2007; 
Rutkute et al., 2007; Tellier et al., 2007). Further insight into the 
functions of this enzyme came with the development of animal 
models lacking nSMase2 activity. Currently, there are two   
nSMase2-deficient mouse models available: one was generated 
by gene targeting (Smpd3
/), whereas the other carries a chemi-
cally induced deletion of 1,758 bp encompassing part of intron 8 
and the adjacent exon 9 of the Smpd3 gene (Aubin et al., 2005; 
Stoffel et al., 2005, 2007). The latter mutation known as fragilitas 
ossium or fro replaces the last 33 amino acids of nSMase2, re-
sulting in a significant reduction of total neutral sphingomyelin-
ase activities in the tissues of the fro/fro mice (Aubin et al., 
2005; Stoffel et al., 2005, 2007). In their recent studies, Stoffel 
et al. (2005, 2007) characterized the skeletal phenotypes of the 
Smpd3
/ mice as a chondrodysplasia and speculated a sys-
temic role for neuronal Smpd3 in the regulation of the skeletal 
development. Although both the Smpd3
/ and fro/fro mutants 
show similar gross skeletal abnormalities, some phenotypic dif-
ferences exist between these two models. For example, the skel-
etal phenotype appears to be milder in Smpd3
/ mice. Also, no 
bone or tooth mineralization defects were reported in this gene-
targeted model. These differences raise the possibility that addi-
tional, as yet unknown, mutations in the chemically mutagenized 
fro/fro model may cause the severe skeletal abnormalities.
The goals of our current study were to characterize the 
skeletal phenotype of fro/fro mice and to investigate the local 
role of Smpd3 in osteoblasts. Toward these goals, we performed 
a detailed characterization of the skeletal tissues in fro/fro  279 nSMase2 and bone mineralization • Khavandgar et al.
Figure 1.  Skeletal abnormalities in fro/fro mice. (A and B) Alizarin red (stains mineralized tissues)– and Alcian blue (stains cartilage matrix)–stained 
skeletal preparations of 2-d-old wild-type (WT) and fro/fro mice showing hypomineralization of the calvaria (a) and short (b) and bent (c) fore- and hind 
limbs in the latter genotype. (C) Micro-CT analysis of 2-d-old WT and fro/fro heads confirming severe hypomineralization of various head skeletal ele-
ments as seen from the dorsal (left) and the lateral (right) views. (D) Light micrographs of von Kossa–stained mineral (black) in parietal (top) and alveolar 
bone (bottom) sections of a 2-d-old WT mouse and its fro/fro littermate. There is a marked decrease in mineralization, revealed by extensive areas of 
unmineralized osteoid (asterisks) in the fro/fro bones. (E) Von Kossa and van Gieson staining of vertebral bones from 1-mo-old WT and fro/fro littermates 
demonstrating a marked increase of unmineralized bone volume (pink staining) in the latter genotype (n = 5). (F and G) Comparison of the percentage 
of osteoid volume over total bone volume (OV/BV) and osteoid surface over bone surface (OS/BS) in WT and fro/fro mice (n = 5). Error bars represent 
standard deviations. *, P < 0.05; **, P < 0.01.JCB • VOLUME 194 • NUMBER 2 • 2011   280
bones of their +/fro littermates (Fig. 3, A and B). This poor 
mineralization was not attributable to impaired osteoblast dif-
ferentiation, as osterix (SP7) immunopositive cells were present 
in the cortical bones of the fro/fro mice (Fig. 3, C and D). Also, 
alkaline phosphatase activity was detected within the unminer-
alized matrix of the fro/fro bones, further indicating that osteo-
blast differentiation was not affected (Fig. 3, E and F). We next 
prepared total RNAs from the bones of newborn WT and fro/fro 
mice and examined the effects of the fro mutation on the expres-
sion of Runx2 and Atf4, encoding two key transcription factors 
involved in early and late osteogenic differentiation, respec-
tively. In agreement with our histological analysis of the embry-
onic mice, quantitative real-time PCR (qRT-PCR) analysis 
showed that the expression of these osteoblast marker genes 
were not altered in fro/fro bones (Fig. S1).
Although  osteoblast  differentiation  was  not  affected  in 
fro/fro mice, we did not observe any osterix-positive cells in the 
marrow space in the long bones of fro/fro embryos, whereas in-
filtration of osteoblast progenitors into the marrow space was 
normal in their +/fro littermates. Instead, we observed an un-
usual persistence of hypertrophic chondrocyte-like cells in the 
cells, and the expression of both WT and mutated proteins was 
confirmed by Western blotting (Fig. 2 C). As shown in Fig. 2 D, 
there was a marked increase in nSMase activity in cells trans-
fected with CMV-Smpd3 but not with the CMV-mSmpd3 con-
struct. We next examined the membrane localization of the WT 
and mutated nSMase2 proteins by indirect immunofluorescence 
and confocal microscopy using an antibody raised against the 
FLAG tag. Importantly, there was no alteration in the membrane 
localization pattern of mutant nSMase2 when compared with 
the WT protein (Fig. 2 E). These data confirm that the mutation 
of the predicted active site is the sole reason for the loss of cata-
lytic activity of this enzyme in fro/fro mice.
The fro mutation affects  
skeletal development
To investigate the effects of the fro mutation on the developing 
skeleton, we performed histological analysis of the long bones 
from embryonic day 15.5 (E15.5) +/fro and fro/fro embryos. 
There was an increased presence of unmineralized collagenous 
matrix in the cortical bones of the humerus (a representative 
long bone) of the fro/fro embryos in comparison to the cortical 
Figure 2.  Effects of fro mutation on nSMase2 activity and localization. (A and B) Schematic depiction of WT (Smpd3; A) and mutant Smpd3 (mSmpd3; 
carries fro mutation; B) expression constructs. The red boxes represent the FLAG coding sequence (CMV, cytomegalovirus promoter; IRES, internal ribo-
some entry site; and pA, SV40 polyadenylation signal). (C) Western blots showing expression of WT and mutant nSMase2 in transfected MCF-7 cells. 
FLAG-tagged proteins from the transfected cells were detected using an anti-FLAG (top) or an anti–mouse nSMase2 (middle) antibody. UT, untransfected. 
(D) A mixed micelle assay using 
14C-labeled methyl-sphingomyelin shows that mutated nSMase2 does not have any nSMase activity. Error bars represent 
standard deviations. (E) Indirect immunofluorescence microscopy analyses showing comparable cell membrane localization of WT and mutated nSMase2 
(shown in red) in transfected MCF-7 cells. The green and blue stains represent GFP localization and the nucleus, respectively. **, P < 0.01.281 nSMase2 and bone mineralization • Khavandgar et al.
comparison to the corresponding areas of the +/fro bones con-
firmed that there was indeed a reduction of the apoptosis of fro/
fro hypertrophic chondrocytes (Fig. 3, G and H).
The presence of ALPL activity in the developing fro/fro 
bones suggests normal PPi hydrolysis in the ECM. However, the 
PPi levels in the ECM may increase because of an up-regulation of 
Enpp1 and Ank, which encode two proteins critical for the mainte-
nance of tissue homeostasis of this mineralization inhibitor 
midshaft regions of the fro/fro long bones (Fig. 3, C and D).   
A possible explanation for this observation might be that the 
hypertrophic  chondrocytes  in  these  mutant  bones  were  not 
undergoing apoptosis at a rate comparable with that of +/fro  
hypertrophic  chondrocytes.  To  investigate  this  possibility, 
we performed TUNEL assay on the humerus sections from both 
+/fro and fro/fro embryos at E15.5. A decreased presence of 
TUNEL-positive  nuclei  in  the  fro/fro  hypertrophic  zones  in 
Figure 3.  Effects of fro mutation on the de-
veloping skeleton. (A and B) Von Kossa and 
van  Gieson  staining  of  the  humerus  from 
E15.5 +/fro and fro/fro embryos. Note the 
unmineralized  cortical  bones  (arrow)  and   
the  expanded  hypertrophic  zone  (asterisk) 
in the fro/fro mice. (C and D) Immunostaining 
of  humerus  sections  from  E15.5  +/fro  and 
fro/fro embryos using an antiosterix antibody 
shows osteoblast differentiation is unaffected 
in the latter genotype. For each panel, a mag-
nified  view  of  the  marked  area  has  been   
shown in the insets. (E and F) Incubation with 
a chromogenic substrate solution demonstrates 
the comparable presence of alkaline phospha-
tase activities in the +/fro and fro/fro bone 
sections.  (G  and  H)  TUNEL  assay  showing 
impaired apoptosis of hypertrophic chondro-
cytes in developing fro/fro endochondral bones 
(n = 4). Arrowheads indicate the TUNEL-positive 
cell nuclei. (I) qRT-PCR showing a mild down-
regulation of Enpp1 expression in the parietal 
bones from fro/fro mice. Note that there is 
no significant alteration of Ank, Mgp, and 
Col1a1 expression in fro/fro bones. RQ, rela-
tive quantification. (J) PPi levels are comparable 
in both WT and fro/fro bone samples. Error 
bars represent standard deviations. *, P < 0.05; 
**, P < 0.01.JCB • VOLUME 194 • NUMBER 2 • 2011   282
the presence of ascorbic acid and -glycerol phosphate, fro/fro 
osteoblast cultures showed reduced mineralization in comparison 
to the +/fro cultures (Fig. 4 G).
Osteoblast-specific expression of Smpd3  
in fro/fro mice increases bone  
nSMase activity
Collectively, a decline of total nSMase activity in fro/fro bones 
and reduced in vitro mineralization by fro/fro osteoblasts (Fig. 4, 
D and G) strongly suggest a local and specific role for nSMase2 
in bone. To investigate this in vivo, we overexpressed Smpd3 
specifically in the bones of fro/fro mice. For this purpose, we 
generated a Col1a1-Smpd3 transgene construct using a 2.3-kb 
Col1a1 promoter fragment, earlier shown to be specifically ex-
pressed in osteoblasts (Fig. 5 A). Pronuclear injection of this 
construct into fertilized mouse eggs resulted in four founders, of 
which two showed bone-specific expression of the transgene. 
No transgene expression was detected in any other tissue in 
these founders (Fig. 5 B). These founders were then mated with 
+/fro mice to first generate +/fro;Col1a1-Smpd3 mice, which 
were mated again with +/fro mice to obtain fro/fro;Col1a1-
Smpd3 mice.
By visual examination, there was no gross skeletal abnor-
malities in the fro/fro;Col1a1-Smpd3 mice. Also, these mice 
survived the perinatal death routinely seen in fro/fro mice (de-
scribed in Fig. 6). In agreement with our transgene expression 
data, we observed a threefold increase of total nSMase activities 
in the bones of newborn fro/fro;Col1a1-Smpd3 mice in compar-
ison to the bones of fro/fro mice, whereas brain nSMase activi-
ties remained indistinguishable between these two genotypes 
(Fig. 5 C). Interestingly, despite a significant increase of bone 
nSMase activities in fro/fro;Col1a1-Smpd3 mice, there was no 
detectable decrease of total bone sphingomyelin levels (Fig. 5 D). 
However, an increase of total ceramide levels in the bones of 
fro/fro;Col1a1-Smpd3 mice was observed when compared with 
the fro/fro bones (Fig. 5 E). Interestingly, we found a significant 
increase of several long-chain ceramide species (e.g., C16, C24, 
and C24:1) in the bones of the former genotype (Fig. 5 F). No 
significant alterations were observed in total dihydroceramide 
levels in the bone extracts prepared from any of the mouse models 
analyzed (Fig. 5 G). Also, several known serum parameters   
affecting ECM mineralization (e.g., calcium, Pi, and alkaline 
phosphatase levels) were unaltered in the fro/fro;Col1a1-Smpd3 
mice (Fig. 5, H–J).
Finally, we compared the expression of Enpp1, Ank, Mgp, 
and Col1a1 by qRT-PCR in the parietal bones of newborn fro/fro 
and fro/fro;Col1a1-Smpd3 mice. We observed significant up-
  regulation of Enpp1 and Ank, but not Mgp, expression. Col1a1 
gene  expression  was  mildly  up-regulated  in  fro/fro;Col1a1-
Smpd3 bones in comparison with fro/fro bones (Fig. S2).
Normal bone mineralization in  
fro/fro;Col1a1-Smpd3 mice
We next examined the skeletal phenotype in fro/fro;Col1a1-
Smpd3 mice. Micro-CT analysis of the humerus from 15.5- 
d-old fro/fro embryos showed poorly mineralized cortical bones, 
which were fully mineralized in the fro/fro;Col1a1-Smpd3 
(Ho et al., 2000; Hessle et al., 2002). We analyzed the expres-
sion of these two genes by qRT-PCR and found that there was in 
fact a mild down-regulation of Enpp1 expression in the bones of 
newborn fro/fro mice, whereas Ank expression was not altered 
(Fig. 3 I). Also, we did not observe any up-regulation of Mgp 
and Col1a1 expression (Fig. 3 I). We then used a fluorogenic 
sensor to measure PPi levels in the bones of adult WT and fro/fro 
mice. We observed that PPi was present at comparable levels   
in the bone samples from both genotypes (Fig. 3 J). Collec-
tively, these data suggest that the hypomineralization defect 
seen in fro/fro mice was not caused by the increase of MGP or 
PPi in the bone ECM.
Loss of nSMase2 in osteoblasts affects 
mineralization in vitro
We  next  examined  Smpd3  expression  in  late-stage  mouse   
embryos and also in tissues collected from WT mice at the pre-
weaning age. The sense and antisense probes generated from   
the Smpd3 cDNA were hybridized separately on fixed whole-
  embryo paraffin sections prepared from E16.5 WT embryos. 
The in situ hybridization analysis performed with the antisense 
probe showed a high level of Smpd3 expression in all bone types, 
cartilage, and in the brain (Fig. 4 A). A similar Smpd3 expression 
pattern was also observed in 2-wk-old mice (Fig. 4 B). Next,   
we examined Smpd3 expression during the differentiation of 
MC3T3-E1 preosteoblasts cultured in the presence of ascorbic 
acid and -glycerol phosphate. Under these culture conditions, 
we observed a progressive induction of Smpd3 expression, which 
was down-regulated in fully mature osteoblasts (Fig. 4 C).
A high level of expression of Smpd3 in embryonic and 
postnatal bones and in a differentiating osteoblastic cell line 
suggests a local role for this enzyme in bone. To examine 
whether nSMase2 deficiency in fro/fro bones causes a reduction 
of total nSMase activity, we prepared calvarial bone extracts 
from both +/fro and fro/fro mice and performed an in vitro en-
zymatic  assay  using 
14C-labeled  sphingomyelin  (Marchesini   
et al., 2003). As a control experiment, we performed the same 
analysis on the extracts prepared from both +/fro and fro/fro 
brain tissues. As shown in Fig. 4 D, there was a comparable de-
crease of nSMase activities in both brain and bone extracts from 
fro/fro mice.
We next investigated whether a loss of nSMase2 activity 
affects the in vitro mineralization capacities of cultured osteo-
blasts. First, we transfected MC3T3-E1 preosteoblasts with 
siRNA oligonucleotides to knock down Smpd3 gene expres-
sion. Gene expression analysis by qRT-PCR revealed that there 
was an 60% reduction of Smpd3 expression in the siRNA-
transfected cells (Fig. 4 E). We cultured both control and Smpd3 
siRNA-transfected cells in the presence of ascorbic acid and   
-glycerol phosphate to induce differentiation and mineralization. 
Upon culturing for 10 d in the aforementioned medium, cells 
were stained with Alizarin red, a calcium-binding dye. We ob-
served reduced mineralization in the cultures with Smpd3 
siRNA-transfected cells in comparison to the cultures with control 
siRNA-transfected cells (Fig. 4 F). This observation was further 
confirmed in experiments performed with primary osteoblasts 
isolated from the newborn +/fro and fro/fro mice. When cultured in 283 nSMase2 and bone mineralization • Khavandgar et al.
Figure 4.  Smpd3 expression and function in osteoblasts. (A) In situ hybridization showing Smpd3 expression in different skeletal elements in an E16.5 
WT mouse embryo. The magnified views of the areas in red boxes are shown in A1 and A2 (PB, parietal bone of the skull cap; BR, brain; PO, periosteum 
in the rib; and RC, rib cartilage). Red stain represents the localization of the Smpd3 transcript, whereas the blue stain represents the nucleus. (B) qRT-PCR 
showing high levels of Smpd3 expression in bone, brain, and cartilage. Tissues were collected from a 2-wk-old WT mouse. All expression analyses were 
performed using hypoxanthine guanine phosphoribosyl transferase (Hprt) expression in the tissue as an internal control and Smpd3 expression in the bone 
as a calibrator (RQ, relative quantification). (C) Smpd3 and Bglap1 (red and blue lines, respectively) gene expression analysis in differentiating MC3T3-E1 
preosteoblasts at five different time points. Smpd3 expression reaches its peak by day 6. Late osteoblast marker Bglap1 expression was used to monitor 
terminal differentiation of the MC3T3-E1 cells. (D) A mixed micelle assay using 
14C-labled methyl-sphingomyelin shows a significant decrease in nSMase 
activity in both brain and bone tissues collected from the fro/fro mice. (E) Smpd3 knockdown by using an siRNA technique in MC3T3-E1 preosteoblasts. 
(F) Alizarin red staining shows reduced in vitro mineral deposition in cultures of MC3T3-E1 cells transfected by Smpd3 siRNAs in comparison with the 
control group. (G) Alizarin red staining shows reduced mineral deposition in cultures of differentiated fro/fro osteoblasts in comparison with the +/fro 
osteoblasts. The cultures were grown for 10 d in an osteogenic medium containing ascorbic acid and -glycerol phosphate. Error bars represent standard 
deviations. **, P < 0.01.JCB • VOLUME 194 • NUMBER 2 • 2011   284
We observed that, as was the case in the long bones from the 
fro/fro mice, the marrow compartment in the long bones of   
fro/fro;Col1a1-Smpd3 mice was full of densely packed chondro-
cytes within a cartilage matrix (Fig. 6 B). We next examined the 
skeleton of newborn fro/fro;Col1a1-Smpd3 mice. Osteoblast-
specific expression of Smpd3 completely corrected the fro/fro 
skeletal abnormalities (Fig. 6 C). X-ray analysis showed that there 
embryos at the same developmental stage. Interestingly, a re-
duced presence of mineral in the marrow compartment of both 
fro/fro and fro/fro;Col1a1-Smpd3 long bones was noted, indi-
cating that the chondrocyte phenotype was largely unaffected in 
the latter genotype (Fig. 6 A). The aforementioned observation 
was further confirmed by Alcian blue staining of the humeri 
sections  from  WT,  fro/fro,  and  fro/fro;Col1a1-Smpd3  mice.   
Figure 5.  Biochemical analysis of tissue and serum samples from fro/fro;Col1a1-Smpd3 mice. (A) Schematic representation of the Col1a1-Smpd3 
transgene construct. (B, top) Semiquantitative PCR analysis confirming bone-specific expression of the transgene (TG). (bottom) Hprt expression analysis 
has been shown as a control for the cDNA amount. Amplicon sizes in base pairs are indicated on the left. (C) Enzymatic assays using 
14C-labled methyl-
  sphingomyelin shows no change in nSMase activity in fro/fro;Col1a1-Smpd3 brain samples. As expected, in fro/fro;Col1a1-Smpd3 bone samples, 
the nSMase activity is increased in comparison with the fro/fro bone samples. (D–G) Lipid analysis using liquid chromatography/mass spectrometry of 
sphingomyelin (D), total ceramide (E), individual ceramide species (F), and dihydroceramide (G). A significant increase of total ceramide levels is caused 
by the increase of several long-chain ceramide species in fro/fro bones (n = 4). (H–J) Serum calcium (H), Pi (I), and alkaline phosphatase (J) activities are 
comparable in +/fro, fro/fro, and fro/fro;Col1a1-Smpd3 mice (n = 5). Error bars represent standard deviations. *, P < 0.05; **, P < 0.01.285 nSMase2 and bone mineralization • Khavandgar et al.
Figure 6.  Analysis of fro/fro;Col1a1-Smpd3 bones. (A) Micro-CT analysis of E15.5 fro/fro humerus showing a poorly mineralized bone collar and carti-
lage matrix. Although bone collar mineralization defects are completely rescued in fro/fro;Col1a1-Smpd3 embryos, mineralization defects in the cartilage 
matrix are still present. Insets show the cross-sectional x-ray images of the analyzed bones. (B) Alcian blue and van Gieson staining of humerus sections 
from E15.5 fro/fro embryos confirm the micro-CT findings. Note the abnormal presence of the hypertrophic chondrocyte-like cells in the shaft region of the 
fro/fro humerus. This latter phenotype is largely unaffected in the fro/fro;Col1a1-Smpd3 long bones. (C) Skeletal preparations indicate a full rescue of the 
fro/fro bone deformities (arrows) in the newborn fro/fro;Col1a1-Smpd3 mice. (D) Radiographical analysis shows that the limb abnormalities are absent 
in 1-mo-old fro/fro;Col1a1-Smpd3 mice. (E) Von Kossa and van Gieson staining of vertebral bone sections from 1-mo-old fro/fro and fro/fro;Col1a1-
Smpd3 littermates demonstrate a complete rescue of the mineralization defects in the latter genotype. (F) Table showing genotyping data. Skeletal abnor-
malities were not seen in any of the fro/fro;Col1a1-Smpd3 mice analyzed.JCB • VOLUME 194 • NUMBER 2 • 2011   286
Our current study establishes an osteoblast-specific role 
of Smpd3 in bone mineralization and several lines of evidence 
suggest that the Smpd3-encoded enzyme nSMase2 acts as a   
local modulator of ECM mineralization in bone. First, Smpd3 is 
highly expressed in bone, and its expression progressively in-
creases as osteoblasts mature. Second, loss of Smpd3 expres-
sion in both siRNA-treated MC3T3-E1 preosteoblasts and in 
fro/fro primary osteoblasts causes impaired mineral deposition 
in cultures. Finally, osteoblast-specific expression of Smpd3 in 
fro/fro bones completely rescues the skeletal abnormalities. 
Collectively, all these findings provide unambiguous demon-
stration of a direct osteoblast/mineralization effect for the   
locally  synthesized  nSMase2  in  osteoblasts.  Furthermore,  a 
normal skeletal appearance in fro/fro;Col1a1-Smpd3 mice sug-
gests that the loss of nSMase2 activity in osteoblasts is the   
major cause of the fro/fro phenotype.
At this point, we cannot fully rule out an indirect systemic 
effect of nSMase2 enzymatic activity from other tissues on the 
developing skeleton. However, in view of our findings that   
osteoblast-specific expression of Smpd3 in fro/fro mice corrects 
the bone but not the cartilage phenotype, we do not consider this 
as a likely possibility. This latter finding also suggests a tissue-
specific role for nSMase2 in the developing skeleton with ap-
parent independent roles in bone and cartilage.
Both fro/fro and the gene-targeted Smpd3
/ mice share 
similar gross skeletal abnormalities, i.e., short-limbed dwarf-
ism, deformation of long bones, abnormally formed rib cages, 
and abnormalities in growth plate cartilage. However, Stoffel   
et al. (2005, 2007), in their gene-targeted model, did not ob-
serve bone and tooth mineralization abnormalities, which are 
seen in all fro/fro mice. This apparent discrepancy can be ex-
plained by differences in the analytical methods used to charac-
terize the two mouse lines. Stoffel et al. (2005, 2007) analyzed 
the mineralization status of the Smpd3
/ mice solely by bone 
mineral density analysis, which determines the total bone min-
eral content and is not suitable for detecting an increase in un-
mineralized bone matrix. In contrast, we analyzed the fro/fro 
bones using a histomorphometric technique on undecalcified 
samples, commonly used to detect skeletal mineralization defects.
Although Stoffel et al. (2005, 2007) suggested that the 
phenotypic variations in fro/fro and Smpd3
/ mice can be at-
tributable to the presence of any additional genetic alterations in 
the former strain, such mutations would have been fully segre-
gated during the propagation of fro/fro mice in multiple labora-
tories over the last two decades. This inference, together with 
the observation that the fully penetrant fro/fro phenotype, in-
cluding the severe hypomineralization defect, is always associ-
ated with the Smpd3 deletion mutation reported by Aubin et al. 
(2005), clearly identifies the loss of nSMase2 function as the 
sole cause of the fro/fro phenotype. Indeed, our current data showing   
a complete rescue of the skeletal phenotypes in fro/fro;Col1a1-
Smpd3  mice  expressing  Smpd3  in  osteoblasts  rules  out  the 
possibility of the presence of any additional mutation in fro/fro 
mice that may cause the observed mineralization defects.
Our results demonstrate an intrinsic loss of nSMase ac-
tivity attributable to the fro mutation. The translocation of   
nSMase2 from the Golgi compartment to the plasma membrane 
was no recurrence  of  the  skeletal  abnormalities  in  the  adult   
fro/fro;Col1a1-Smpd3 mice (Fig. 6 D). Also, we observed an 
absence of abnormally high osteoid volume in the bones of 
this latter model (Fig. 6 E).
We analyzed a total of 144 mice from the aforemen-
tioned breeding experiments, of which 17 were fro/fro. All of 
these mice had limb deformities, and 11 of them died peri-
natally. On the other hand, out of a total of 28 fro/fro;Col1a1-
Smpd3 mice generated through this breeding, only three died 
perinatally, whereas none of them showed any kind of skele-
tal abnormalities (Fig. 6 F). We tested the significance of 
these data using the standard Pearson’s 
2 test and found that 
for the rescue of both skeletal phenotype and perinatal death, 
the  p-values  were  far  below  the  commonly  accepted  5% 
threshold for significance.
Discussion
Analysis  of  novel,  genetically  modified  mouse  models  with 
skeletal and dental mineralization defects may provide critical 
information on as yet unidentified regulators of ECM mineral-
ization and, thereby, improve our understanding of this impor-
tant physiological process. Recently, a loss-of-function mutation 
in the Smpd3 gene has been identified in a mouse model (fro/fro), 
which  shows  severe  bone  and  tooth  mineralization  defects 
(Guenet et al., 1981; Aubin et al., 2005). The fro/fro skeletal ab-
normalities are similar to the skeletal pathology seen in pa-
tients with certain forms of osteogenesis imperfecta that do not   
involve any mutation in collagen genes (Glorieux et al., 2002). 
As is the case with these patients, the most common parameters 
affecting ECM mineralization, e.g., serum calcium, Pi, and al-
kaline phosphatase levels, are not decreased in fro/fro mice. 
Furthermore, when analyzed by histology, the unmineralized 
bone matrix appears to be secreted normally in these mice.   
Collectively,  these  observations  suggest  that  Smpd3  might   
affect ECM mineralization through a novel mechanism.
In an earlier study, the skeletal phenotype of Smpd3
/ 
mice has been described as a form of chondrodysplasia (Stoffel 
et al., 2005). In agreement with this finding, we observed a sig-
nificantly impaired apoptosis of hypertrophic chondrocytes, 
possibly caused by reduced ceramide levels during early skele-
tal development in fro/fro embryos. Additionally, we also ob-
served poor mineralization of the matrix secreted by osteoblasts 
that severely affects the strength of the cortical bones in these 
embryos. This novel finding explains the long bone deformities 
in fro/fro mice.
Our data suggest that hypomineralization of bone ECM in 
fro/fro mice is not caused by the elevated levels of mineraliza-
tion inhibitors MGP or PPi (Fig. 3, I and J). We observed a mild 
down-regulation of Enpp1 in fro/fro bones, whereas both Ank 
and Enpp1 expressions were significantly up-regulated in the 
bones of fro/fro;Col1a1-Smpd3 mice. Interestingly, up-regulation 
of these two genes in the latter model did not prevent the rescue 
of the bone mineralization defects. These data suggest that   
there might be a compensatory interplay between the positive   
(nSMase2) and negative (ANK and ENPP1) regulators of bone 
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The data we present here suggest that a local nSMase2 function 
is required for a normal bone mineralization and for the normal 
apoptosis of hypertrophic chondrocytes in the cartilage during 
early  skeletal  development  (Fig.  7).  Collectively,  these  data 
demonstrate, for the first time, the tissue-specific roles for this 
enzyme in the developing skeleton. Further analyses of the 
mouse models reported here may reveal the molecular mecha-
nisms underlying the pathophysiology of certain forms of osteo-
malacia and osteogenesis imperfecta in humans.
Materials and methods
DNA constructs
The DNA construct for osteoblast-specific expression of the Smpd3 trans-
gene was generated using a 2.3-kb Col1a1 promoter fragment (Rossert   
et al., 1995). A full-length Smpd3 cDNA (American Type Culture Collec-
tion) preceded by a rabbit -globin intron was inserted in between the 
Col1a1 promoter fragment and a SV40 polyadenylation signal. The trans-
gene sequence was released from the plasmid backbone by SacII restric-
tion  digestion  and  was  used  for  pronuclear  injection.  A  PCR-based 
technique was used to introduce the fro mutation into the WT cDNA. Both 
WT  and  mutant  (fro)  Smpd3  cDNAs  were  cloned  in  pIRES-hrGFP-1  
(Agilent Technologies).
Mice
Generation of fro/fro mice was described previously (Aubin et al., 2005). 
Transgenic  founders  were  generated  by  pronuclear  injections  at  the   
McIntyre Cancer Center Transgenic Core Facility at McGill University fol-
lowing standard techniques. All mice were maintained in a pathogen-free 
standard animal facility, and the experimental procedures were performed 
following an animal use protocol approved by the Animal Care Committee 
of  McGill University.  Genotypes were  determined  by  PCR  on  genomic 
DNAs isolated from the tail biopsies. The following primers were used for 
the genotyping of the fro mutation: 5-GGGACGACGTCTGCCTCAGG-3, 
5-TTAGAGGTCCCAACCACAGG-3, and 5-CCCAGGTGCTGGGCA-
GAAGG-3. With these three primers, it is possible to amplify specific WT 
(145 bp) and mutant (189 bp) DNA fragments. The Col1a1-Smpd3 trans-
gene integration was detected using the following primer pair specific for 
the SV40 polyadenylation signal: 5-CAGCTCTCCATCAAGATGGT-3 and 
5-CCGGTTTGGACTCAGAGTAT-3.
Gene expression analysis
Gene expression analyses were performed using a qRT-PCR system (model 
7500; Applied Biosystems). Total RNA was extracted from different tissues 
with TRIZOL reagent (Invitrogen) and subjected to DNase I (Invitrogen) 
treatment. The first-strand cDNA synthesis and qRT-PCR were performed   
using a high-capacity cDNA reverse transcription kit (Applied Biosystems) 
and SYBR green quantitative PCR master mix (Maxima; Fermentas), respec-
tively. The following primer pairs were used: 5-AGAAACCCGGTCCTCG-
TACT-3  and  5-CCTGACCAGTGCCATTCTTT-3  for  Smpd3  expression 
and its recycling back to the Golgi is a highly dynamic and   
regulated process. Notably, preventing nSMase2 recycling has 
been shown to increase nSMase activity and ceramide levels, 
suggesting adverse physiological consequences for alterations 
in localization of this enzyme (Milhas et al., 2010). Considering 
the critical nature of this process, we examined whether the re-
duced nSMase activities in fro/fro tissues are attributable to an 
impaired nSMase2 localization or are caused by the loss of its 
catalytic activity. Our cell culture data confirm that the mutant 
nSMase2 localizes identically to WT nSMase2 and indicate that 
the reduced tissue nSMase activity in fro/fro mice is likely to be 
caused by the disruption of the enzyme’s catalytic site.
nSMase2 cleaves sphingomyelin to generate the lipid sec-
ond messenger ceramide (Merrill et al., 1997; Wu et al., 2010). 
Thus, a loss of functional nSMase2 could have dual effects, i.e., 
both a decrease in ceramide levels and an increase in sphingo-
myelin levels in tissues in which Smpd3 is normally expressed. 
Indeed, a recent study suggested a crucial role for sphingo-
myelin and its degradation in bone and dentin mineralization 
(Goldberg et al., 2008). However, as sphingomyelin, being an 
integral component of all cell membranes, is present in all tis-
sues in relatively high amounts and because only a small frac-
tion of it is cleaved by the nSMase2 enzymatic activity, a 
loss-of-function mutation in Smpd3 as such may not have any 
significant effects on the total tissue sphingomyelin levels.   
Indeed, we did not observe any difference in total sphingomyelin 
levels between +/fro and fro/fro bones. This observation sug-
gests that increased sphingomyelin levels in bone attributable to 
the loss of nSMase2 activity may not account for the ECM min-
eralization defects in fro/fro mice. Although we could not detect 
any  significant  alteration  in  tissue  sphingomyelin  levels,  we 
found a remarkable decrease of various ceramide species, par-
ticularly those with long chains, in fro/fro bones in comparison 
to the control +/fro bones. Currently, it is not clear how cer-
amide might affect bone ECM mineralization. Ceramide acting 
as a second messenger can affect several signaling pathways 
and may alter as yet unknown downstream regulators critical 
for bone ECM mineralization.
In  conclusion,  the  fro/fro  mice  lacking  a  functional   
nSMase2 provide a unique opportunity to investigate a novel 
mechanism involved in vertebrate hard tissue mineralization. 
Figure  7.  A  model  depicting  the  local  ac-
tivities  of  nSMase2  in  skeletal  tissues.  The 
cell-autonomous  activity  of  nSMase2  in  bone 
promotes ECM mineralization. In the cartilage, 
nSMase2 enzymatic activity is necessary for the 
normal apoptosis of hypertrophic chondrocytes.JCB • VOLUME 194 • NUMBER 2 • 2011   288
The cross sections along the specimen long axis were reconstructed using 
NRecon software (SkyScan), with a distance between each cross section of 
9.58 µm. Each cross section was reduced in half-size to facilitate the analy-
sis, giving of a voxel of 9.58 × 9.58 × 9.58 µm
3. CT-Analyser and 3D Cre-
ator software (both from SkyScan) were used to analyze and to perform 3D 
rendering, respectively.
Serum biochemistry
Serum calcium and Pi levels were measured using commercially available 
kits (Diagnostic Chemicals Limited). Serum ALPL levels were measured as 
described previously (Li et al., 2011), whereas tissue PPi levels were mea-
sured using a fluorogenic sensor following the manufacturer’s instructions 
(Advancing Assay Technologies Bioquest, Inc.).
Sphingomyelinase assays and lipid measurements
Limbs and skullcaps were snap frozen in liquid nitrogen and crushed 
before further homogenization in 20 mM Tris buffer containing prote-
ase  inhibitors  using  an  autohomogenizer.  Brain  tissue  was  homoge-
nized directly in the same buffer. Aliquots of homogenate were removed 
for the estimation of protein concentration by the Bradford assay. In vitro 
analysis of nSMase activity was performed using a mixed micelle assay 
as described previously (Marchesini et al., 2003). In brief, duplicate al-
iquots (20–30 µg protein) of homogenate were diluted to 100 µl in   
neutral  buffer  containing  25  mM  Tris,  pH  7.4,  5  mM  EDTA,  0.2%   
Triton X-100, and protease inhibitors. The reaction was started by add-
ing 100 µl assay buffer containing 200 µM sphingomyelin, 100 µM 
phosphatidylserine, and 100,000 cpm 
14C-labeled methyl-sphingomyelin 
reconstituted in 25 mM Tris, pH 7.4, 10 mM MgCl2, 5 mM DTT, and 
0.2% Triton X-100. After incubation for 30 min at 37°C, reactions were 
stopped by the addition of 1.5 ml chloroform/methanol (2:1). 400 µl of 
water was added, and samples were vortexed and spun at 3,000 rpm 
for 5 min at room temperature. Next, 800 µl of the upper phase was 
added to 4 ml scintillation fluid, vortexed, and counted. 10 µl assay 
buffer, representing 2 nmol sphingomyelin, was also counted to allow 
conversion of results from counts per minute to picomoles of ceramide 
per milligram of protein per hour. For lipid analysis by mass spectrome-
try, after homogenization, lysate containing 200 µg–1 mg protein was 
analyzed  for  sphingomyelin,  ceramide,  and  dihydroceramide  levels   
by  tandem  liquid  chromatography/mass  spectrometry  as  previously   
described  (Bielawski  et  al.,  2010).  Lipid  levels  were  normalized  to   
cellular protein.
Data analysis
All results are shown as means ± the standard deviation. Statistical analy-
ses were performed by Student’s t test, with P < 0.05 considered significant 
as indicated by a single asterisk (**, P < 0.01). Standard Pearson’s 
2 test 
was used to test the significance of the rescue of both skeletal phenotype 
and perinatal death.
Online supplemental material
Fig. S1 shows qRT-PCR analysis of Runx2 and Atf4 expression in newborn 
fro/fro bones. Fig. S2 shows qRT-PCR analysis of Enpp1, Ank, Mgp, and 
Col1a1 expression in the bones from newborn fro/fro and fro/fro;Col1a1-
Smpd3 mice. Fig. S3 shows qRT-PCR analysis of Runx2, Col1a1, Atf4, 
and Bglap1 expression in the control and Smpd3 siRNA-treated MC3T3-E1   
cells  and  Runx2,  Atf4,  Bglap1,  and  Smpd3  expression  in  WT  and   
+/fro mice. Online supplemental material is available at http://www.jcb 
.org/cgi/content/full/jcb.201102051/DC1.
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and 5-AAGCAGGAGGGCAATAAGGT-3 and 5-CAAGCAGGGTTA-
AGCTCACA-3 for Bglap1 expression. For in situ hybridization analy-
ses, embryos were fixed in 4% PFA, embedded in paraffin, and sectioned 
at  5-µm  thickness.  A  full-length  Smpd3  cDNA  was  used  to  generate   
35S-labeled sense and antisense riboprobes.
Skeletal preparation and histological analysis
Skeletal tissues from newborn and adult mice were fixed overnight in 95% 
ethanol, stained in 0.015% Alcian blue dye (Sigma-Aldrich) in a 1:4 solu-
tion of glacial acetic acid and absolute ethanol for 24 h, and treated with 
2% potassium hydroxide until the soft tissues were dissolved. The mineral-
ized tissues were stained by 0.005% Alizarin red (Sigma-Aldrich) solution 
in 1% potassium hydroxide and clarified in 1% potassium hydroxide/20% 
glycerol for ≥2 d. For plastic sectioning, vertebrae were fixed overnight in 
4%  PFA/PBS,  embedded  in  methyl  methacrylate,  and  sectioned  (7-µm 
thickness), and von Kossa and van Gieson staining was applied. Unminer-
alized bone sections were analyzed using Osteomeasure software (Osteo-
metrics,  Inc.).  Mouse  embryos  were  fixed  in  4%  PFA/PBS,  pH  7.4, 
overnight and embedded in paraffin. 5-µm-thick sections were submitted to 
von Kossa, Alcian blue, and van Gieson staining. Images were taken at 
room temperature using a light microscope (DM200; Leica) with a 20× 
(numerical aperture of 0.40) or 40× (numerical aperture of 0.65) objec-
tive. All histological images were captured using a camera (DP72; Olym-
pus), acquired with DP2-BSW software (XV3.0; Olympus), and processed 
using Photoshop (Adobe). The TUNEL assay was performed on E15.5 em-
bryos to evaluate in vivo chondrocyte apoptosis as per the manufacturer’s 
instructions (Deadend Fluorometric TUNEL System kit; Promega).
Immunofluorescence and confocal microscopy
MCF-7 cells (15 × 10
4/dish) were seeded in 35-mm confocal dishes (MatTek), 
and after 24 h, cells were transiently transfected with 1 µg Smpd3 or 
mSmpd3 cloned in the pIRES-hrGFP-1 expression vector. After 24 h, cells 
were fixed with 3.7% PFA for 10 min, permeabilized with 100% methanol 
for 5 min at 20°C, and blocked with 2% human serum in PBS for 30 min 
at  room  temperature.  Cells  were  probed  with  or  without  anti-FLAG 
(1:1,000; Sigma-Aldrich) antibody in 2% serum for 2 h at room tempera-
ture, washed with 3× PBS, and probed with fluorescent secondary anti-
body (1:200 anti–mouse Alexa Fluor 555; 30–45 min at room temperature). 
After washing with 3× PBS, nuclei were visualized with DRAQ5 staining 
(1:500 in PBS). Images were captured with a confocal microscope (LSM 
510 Meta; Carl Zeiss).
Immunoblotting
Protein samples were separated on 4–20% gradient Tris-HCl gels (Bio-Rad 
Laboratories) at a constant current of 40 mA before transfer to nitrocellu-
lose membrane in Tris/glycine buffer (100 V for 30 min at 4°C). Mem-
branes were blocked (5% milk in 0.1% Tween in PBS for 30 min) and 
incubated overnight at 4°C with anti-FLAG (Sigma-Aldrich), anti-nSMase2 
(Santa Cruz Biotechnology, Inc.), or antiactin (Sigma-Aldrich) primary anti-
bodies at a 1:1,000, 1:500, or 1:20,000 dilution, respectively. Membranes 
were washed (3× in 0.1% Tween in PBS), probed with HRP-conjugated 
mouse or rabbit secondary antibody (1:5,000 in 5% milk in 0.1% Tween 
in PBS) for 30–45 min at room temperature, and washed (3× in 0.1% 
Tween in TBS). Proteins were visualized by enhanced chemiluminescence 
(Thermo Fisher Scientific).
Transient transfection with siRNAs, cell culture, and in vitro mineralization
MC3T3-E1 cells were transfected with 50 ng/µl of Smpd3 (SI01426999; 
QIAGEN)  or  control  (1027284;  QIAGEN)  annealed  double-stranded   
siRNAs and cultured in -MEM (Invitrogen) supplemented with 10% FBS 
(PAA Laboratories) and 100 U/ml penicillin-streptomycin at 37°C under 
5% CO2 in a humidified incubator. Primary osteoblast isolation from cal-
varia, in vitro differentiation and culture, and Alizarin red staining for min-
eral deposition were performed as described previously (Li et al., 2011).
Radiography and micro-CT analysis
Radiography  and  micro-CT  analyses  of  the  skeletal  samples  were  per-
formed at the Centre for Bone and Periodontal Research Core Facility at 
McGill  University  using  an  x-ray  imaging  system  (XPERT;  Kubtec)  and   
micro-CT system (SkyScan), respectively. For micro-CT analyses, the x-ray 
source was operated at 45 kV and at 222 µA (maximum power). Images 
were  captured  using  a  12-bit,  cooled  charge-coupled  device  camera 
(1,024 by 1,024 pixels) coupled by a fiber optics taper to the scintillator. 
Samples were scanned at a magnification resulting in a pixel size of 4.79 µm. 
Using a rotation step of 0.9° and an exposition time of 2,240 ms for   
each step, images were generated, giving a scanning time of 30 min. 289 nSMase2 and bone mineralization • Khavandgar et al.
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